Dec 13, 2011 by Brian Orelli, PhDDividend? Buyback? Here's How to Get Both.But will there be enough to replenish the pipeline?
Dec 8, 2011 by Brian Orelli, PhDA Soaring Biotech With Room to RunAffymax gets a leg up from an FDA advisory panel vote.
Dec 7, 2011 by Brian Orelli, PhDAs the Biotech Saying Goes...Another delay for Protalix BioTherapeutics makes you think.
Dec 6, 2011 by Brian Orelli, PhDPfizer Faces Firing LineA panel of outside experts will help decide Inlyta's fate.
Nov 30, 2011 by Brian Orelli, PhD3 Things More Important to Pfizer Than Losing LipitorIt's not like we didn't see it coming.
Nov 30, 2011 by Brian Orelli, PhDUp Big With Room to RunLofty hep C valuations are par for the course.
Nov 30, 2011 by Brian Orelli, PhDIn Drug Development, Help Is CrucialCuris gets some from the The Leukemia & Lymphoma Society.
Nov 30, 2011 by Brian Orelli, PhDThis $581 Doughnut Hole Costs DrugmakersIt's costing drugmakers money. Can they recoup it elsewhere?
Nov 30, 2011 by Brian Orelli, PhDDrugmakers Bleeding OutThat's not what blood thinners are supposed to do.
Nov 29, 2011 by Brian Orelli, PhDWinners and Losers of Roche's Avastin WoesWhat the FDA giveth, the FDA can taketh away.
Nov 28, 2011 by Brian Orelli, PhDBreaking Down a Biotech Press ReleaseSometimes you have to take a deep dive.
Nov 28, 2011 by Brian Orelli, PhDThe Biggest Fear for Hep C InvestorsWarehousing of patients could continue.
Nov 25, 2011 by Brian Orelli, PhD7 Black Friday Biotech BargainsGet in at the right time to maximize your returns.
Nov 22, 2011 by Brian Orelli, PhDThis Spec Pharma Hopes Convenience Trumps AllSpectrum Pharmaceuticals' Zevalin no longer requires a bioscan.
